- Novo Nordisk confirmed it has written to suppliers seeking price discounts to keep its partnerships “commercially sustainable” — a move Danish business outlet Finans first reported, noting some suppliers received Novo’s correspondence as a threat to future business with the company if they didn’t comply.
- Novo framed the campaign as voluntary (“participation is not mandatory”) but added a pointed caveat: “we take a positive response into account as part of our broader supplier assessment” — language suppliers would likely read as a warning that declining could affect their standing with one of the world’s largest drugmakers.
- The cost pressure reflects Novo’s deteriorating competitive position in the GLP-1 obesity drug market it helped pioneer: rival Eli Lilly has gained significant market share with Zepbound, forcing Novo to slash prices on Wegovy and pivot to a new pill formulation while CEO Mike Doustdar conducts a broader cost-cutting drive that has included job cuts since he took over last year.
- The supplier squeeze comes at an awkward moment: Novo just agreed to sell Wegovy to Medicare at $245/month (versus a list price of up to $1,350) as part of the new Bridge program launching July 1, meaning the company needs to compress its cost structure substantially to maintain margins on government-program volume.
What Happened?
Novo Nordisk confirmed Thursday that it has written to suppliers requesting price concessions, citing the need to keep its cost base “commercially sustainable” as competition in the obesity drug market intensifies. The move was first reported by Danish business outlet Finans, which said some suppliers interpreted the correspondence as a threat — that failure to grant discounts could jeopardize their ongoing relationship with Novo. Novo’s public statement was careful to call participation “not mandatory” while making clear that responsiveness factors into supplier assessments. The pressure campaign sits within CEO Mike Doustdar’s broader cost-cutting agenda, which has included job reductions since he took the helm last year, and comes as Novo faces a two-front squeeze: growing competition from Eli Lilly and pricing pressure from government programs including the new Medicare Bridge deal at $245/month.
Why It Matters?
Novo Nordisk’s supplier pressure campaign is a visible sign of competitive stress at a company that was until recently one of Europe’s most valuable businesses — briefly overtaking LVMH as the continent’s largest company by market cap at the height of the GLP-1 boom. Eli Lilly’s Zepbound has taken meaningful market share with clinical data showing superior weight loss versus Wegovy, and Novo’s response has been to cut prices, launch a pill formulation, and now compress its supply chain costs. The dynamics are structurally significant for the broader GLP-1 market: as the two dominant players compete on price — both now selling to Medicare at deeply discounted rates — margin pressure will intensify across the entire obesity drug ecosystem, including contract manufacturers, ingredient suppliers, and device makers who produce injection pens and packaging.
What’s Next?
Novo’s next major catalyst is the commercial rollout of its Wegovy pill under Medicare’s new Bridge program, which launched July 1. If pill-form adoption proves faster than injection uptake (as Lilly’s US unit head suggested could happen), it would validate Novo’s pivot strategy. On the competitive front, both companies face longer-term pressure from pipeline challengers — including oral-only GLP-1 candidates from Pfizer, Roche, and others — that could compress the duopoly pricing power both have enjoyed. For now, the supplier squeeze signals that Novo is fighting hard on costs to protect margins in a market where it no longer holds the clear clinical or commercial lead it once did.
Source: Bloomberg
